华北制药(600812.SH)：上半年净利润1.23亿元，同比增长71.56%

Core Viewpoint - North China Pharmaceutical (600812.SH) reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating strong financial performance despite a modest revenue growth [1] Financial Performance - The company achieved an operating revenue of 5.275 billion yuan, representing a year-on-year growth of 0.84% [1] - The net profit attributable to shareholders reached 123 million yuan, showing a substantial year-on-year increase of 71.56% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 120 million yuan, reflecting a remarkable year-on-year growth of 120.69% [1] - Basic earnings per share were reported at 0.072 yuan [1]